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A B S T R A C T
Objectives: To describe colistin-resistant Acinetobacter baumannii isolates in Cape Town, South Africa.
Methods: A. baumannii isolates identified on Vitek 2 Advanced Expert System were collected from
Tygerberg Hospital referral laboratory between 2016 and 2017. Colistin resistance was confirmed using
broth microdilution and SensiTest. mcr-1–5 were detected using PCR and strain typing was performed by
rep-PCR. Whole genome sequencing (WGS) was performed on a subset of isolates to identify
chromosomal colistin resistance mechanisms and strain diversity using multilocus sequence typing
(MLST) and pairwise single nucleotide polymorphism analyses.
Results: Twenty-six colistin-resistant and six colistin-susceptible A. baumannii were collected separately
based on Vitek susceptibility; 20/26 (77%) were confirmed colistin-resistant by broth microdilution. Four
colistin-resistant isolates were isolated in 2016 and 16 in 2017, from five healthcare facilities. Thirteen
colistin-resistant isolates and eight colistin-susceptible isolates were identical by rep-PCR and MLST
(ST1), all from patients admitted to a tertiary hospital during 2017. The remaining colistin-resistant
isolates were unrelated.
Conclusions: An increase in colistin-resistant A. baumannii isolates from a tertiary hospital in 2017
appears to be clonal expansion of an emerging colistin-resistant strain. This strain was not detected in
2016 or from other hospitals. Identical colistin-susceptible isolates were also isolated, suggesting
relatively recent acquisition of colistin resistance.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Acinetobacter baumannii is a gram-negative coccobacillus that is
responsible for a substantial proportion of bacterial hospital-
acquired (HA) infections in intensive care units (ICUs) and is
emerging as a leading healthcare-associated pathogen. A. bau-
mannii may colonize the skin, oropharynx, and gastrointestinal
tract without causing infection (Maragakis and Perl, 2008).
However, among immunocompromised hosts, particularly* Corresponding author at: Division of Medical Microbiology, Department of
Pathology, Stellenbosch University, Tygerberg Hospital, Fransie van Zyl Avenue,
Cape Town, South Africa.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).patients in ICU settings, A. baumannii may cause serious infections
including bacteraemia, meningitis, pneumonia, urinary tract
infections, and wound infections. This organism can survive on
dry surfaces, potentiating its ability for nosocomial spread
(Maragakis and Perl, 2008).
A. baumannii is challenging to treat because it can easily
upregulate innate resistance mechanisms and acquire a wide array
of antimicrobial resistance genes (Ewers et al., 2016; Perez et al.,
2007). Carbapenems represent one of the last therapeutic options
for the treatment of infections due to multidrug-resistant (MDR) A.
baumannii.
The emergence of carbapenem resistance has further driven the
need to use colistin as a last therapeutic option to combat MDR
infections. The emergence of colistin resistance has been widely
reported, leading to global concern for the treatment of theseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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mon, but resistance has been reported worldwide (Cai et al., 2012;
Asif et al., 2018).
To date only chromosomally encoded colistin resistance
mechanisms have been reported in A. baumannii. Mutations in
the pmrB/pmrA/pmrC operon and genes encoding lipid A biosyn-
thesis (lpxA, lpxC, lpxD) confer colistin resistance through
modification of the lipid A component of the lipopolysaccharide
(LPS) and through complete loss of LPS, respectively (Moffatt et al.,
2010; Adams et al., 2009; Mu et al., 2016). The presence of the
insertion sequence ISAba11 in lpxC or lpxA also causes inactivation
of LPS production (Moffatt et al., 2011). Alternatively, phosphoe-
thanolamine transferase overexpression can result from the
integration of the ISAbaI upstream of a pmrC homolog eptA
leading to colistin resistance (Trebosc et al., 2019).
Recently, colistin resistance due to the plasmid-mediated mcr-
1–9 genes has been described in numerous bacterial species, but
not A. baumannii (Liu et al., 2016; Xavier et al., 2016; Yin et al., 2017;
Carattoli et al., 2017; Borowiak et al., 2017; Yang et al., 2018;
AbuOun et al., 2017; Wang et al., 2018; Carroll et al., 2019). The mcr-
4.3 variant has been described in an A. baumannii isolate from
China; however this variant does not confer colistin resistance (Ma
et al., 2019). In South Africa, the prevalence of mcr-1 has only been
investigated in Escherichia coli and Klebsiella pneumoniae (Newton-
Foot et al., 2017; Coetzee et al., 2016; Poirel et al., 2016).
It appears that no previous studies have described the
clonal diversity of colistin-resistant A. baumannii isolates in
southern Africa. The objective of this study was to characterize
the colistin resistance mechanisms and molecular diversity of
colistin-resistant A. baumannii isolates recovered from patients
with clinical infections from hospitals in the Western Cape of
South Africa. Surveillance of colistin resistance mechanisms
present in a population is vital for advising effective treatment




The National Health Laboratory Service (NHLS) Microbiology
Laboratory at Tygerberg Academic Hospital receives specimens
from Tygerberg Hospital and various regional and district hospitals
in the Western Cape. Areas from Cape Town, Cape Winelands, West
Coast, and Overberg rural districts are part of the Tygerberg
Hospital catchment area. This hospital serves as a referral centre
for more than 120 primary health care clinics, 17 district hospitals,
and four regional hospitals. Tygerberg Hospital itself is a 1384-bed
tertiary academic hospital, including 176 paediatric beds, 124
neonatal beds, and general and specialist medical and surgical
services.
Isolate collection
A. baumannii isolates were collected from clinical specimens
processed routinely between May 2016 and August 2017; these
isolates were chosen on the basis of being colistin-resistant. In
addition, colistin-susceptible, carbapenem-resistant A. bau-
mannii isolates from the neonatal unit at a tertiary hospital
were collected separately between March and May 2017 as part of
an outbreak investigation. Microbial identification and antimi-
crobial susceptibility testing were performed as part of routine
diagnostic procedures, using the Vitek 2 Advanced Expert System
(BioMérieux). All isolates were initially selected based on
carbapenem and colistin susceptibility results as determined by
the Vitek 2 system.Hospital- or community-acquired isolates/infection
Isolates from the tertiary hospital were classified as communi-
ty- or hospital-acquired (CA or HA) if they were cultured from
specimens collected within 3 days (CA) or after 3 days (HA) of
admission. If a patient had been previously hospitalized for two or
more days within the past 90 days, the isolates were also classified
as hospital-acquired (Kieninger and Lipsett, 2009). A 72-h cut-off
was opted for instead of a 48-h cut-off, as only date of admission
was available, not the specific time. Isolates from outside of the
academic hospital were not classified this way, as admission dates
were not available.
Phenotypic resistance testing
Although isolates were initially selected based on colistin and
carbapenem susceptibility results as determined by the Vitek 2
system, colistin susceptibility was confirmed using SensiTest
Colistin (Liofilchem, Italy) and by broth microdilution (BMD)
following the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) guidelines and breakpoints version 8 (ISO-
standard broth microdilution method 20776- 1) (Eucast, 2016).
Isolates with a minimum inhibitory concentration (MIC) of 2 mg/
ml were classified as colistin-susceptible and those with a
MIC > 2 mg/ml as colistin-resistant. A. baumannii EUCAST-20
(MIC 0.5 mg/ml) and E. coli NCTC 13846 (MIC 2–4 mg/ml) were
included as controls.
PCR detection of mcr genes
PCR detection of mcr-1, -2, -3, -4, and -5 was performed on
colistin-resistant isolates using previously described primers (Liu
et al., 2016; Xavier et al., 2016; Yin et al., 2017; Carattoli et al., 2017;
Borowiak et al., 2017). The rpoB gene product was used as an
internal amplification control (Khosravi et al., 2015), and several
mcr amplification controls were used (NCTC 13846, KP37-BE
(Xavier et al., 2016), WJ1(13), CAC13 (MG948623.2), PLA35
(unpublished sequenced PCR products)). PCR assays were done
using the KAPA Taq ReadyMix PCR Kit (Kapa Biosystems) and
amplicons were separated on a 1.5% w/v agarose gel and detected
using the Alliance 2.7 imaging system (UVITec).
Molecular typing using rep-PCR
The clonal relationship of all A. baumannii isolates was analysed
by rep-PCR using previously described primers: REP 1F 50-
IIIGCGCCGICATCAGGC-30 and REP 2R 50-ACGTCTTATCAGGCCTAC-
30 (Vila et al., 1996). GelCompar II version 7.5 (Applied Maths) was
used for dendrogram construction (http://www.applied-maths.
com/bionumerics). Banding patterns were normalized to the KAPA
Universal Ladder (Kapa Biosystems) and similarity between the
profiles calculated with the band matching Dice similarity
coefficient with 1% position tolerance (Domenech de Cellès
et al., 2012). Dendrograms were generated using the unweighted
pair group method with arithmetic mean (UPGMA) (Domenech de
Cellès et al., 2012). Isolates with 98% similarity were defined as
identical, 95% as closely related, and <94.9% as unrelated (Higgins
et al., 2012).
Whole genome sequencing (WGS)
Four rep-PCR identical isolates were chosen for WGS: two were
colistin-resistant (CAC12 and CAC38) and two colistin-susceptible
(CAC37 and CAC29). Genomic DNA was extracted using the Roche
Pure PCR Template Preparation Kit (Roche Diagnostics, Germany).
The DNA concentration was determined using the Qubit dsDNA BR
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and diluted to 0.2 ng/ml. DNA libraries were prepared using the
Nextera DNA Flex Library Preparation Kit (Illumina, Germany) and
sequenced with the Illumina MiSeq Reagent Kit V2.
Sequencing reads were assessed for sufficient coverage
(>30  based on mapping to reference genome A1 (CP010781))
and assembly statistics (N50 > 100 000 bp; length 4 Mbp; total
number of contigs <100) (Supplementary Material Table S1).
Taxonomic identification was done using Kraken version 0.10.5-
beta with the 4 GB MiniKraken database (Wood and Salzberg,
2014). Assemblies were generated using SPAdes (Bankevich et al.,
2012) and annotated using Prokka (Seemann, 2014). Roary was
used to determine shared gene presence and absence (Page et al.,
2015).
The raw reads have been deposited in the European Nucleotide
Archive (ENA) (PRJEB34692) and the assemblies have been
deposited in the National Center for Biotechnology Information
(NCBI) (Supplementary Table 1).
Genotypic detection of chromosomal resistance mechanisms using
WGS data
Acquired antimicrobial resistance genes and mutations in the
lpxA, lpxC, lpxD, and pmrB/pmrA/pmrC genes were detected using
ARIBA (Hunt et al., 2017) using the CARD (McArthur et al., 2013)
and ResFinder (Zankari et al., 2012) databases. Additionally,
Artemis (Rutherford et al., 2000) was used to manually screen
the annotated assemblies for known colistin resistance mutations
and gene differences (sequence variants and the presence/absence
of genes) in the colistin resistance pathway.
Strain typing using WGS data
Sequence type (ST) was determined from the assemblies
(https://github.com/tseemann/mlst) using the Pasteur scheme
(cpn60, fusA, gltA, pyrG, recA, rplB, rpoB). Reads were mapped
against the first collected colistin-susceptible A. baumannii isolate
(CAC29) and single nucleotide polymorphisms (SNPs) were
identified. From the resulting alignment, a pairwise SNP distance
matrix was generated using snp-dists 0.6.3 (https://github.com/
tseemann/snp-dists). This presented the relatedness of these
isolates with the highest possible resolution. SNPs were manually
viewed in Artemis to check for their quality to eliminate those
called due to errors in sequencing or mapping accuracy.Figure 1. Colistin resistant and susRT-PCR detection of the I527N mutation
Real-time PCR (RT-PCR) was performed on all colistin-resistant
and susceptible isolates using two sets of primers that are specific
for the I527N mutation, I527N1-YF 50-CTAAAGAGGCACCAGCTT-
TAAATAA-30 and I527N1-YR 50-ACCAAGACGGAACTGTGAA-30, and
wild-type sequence I527N2-YF 50-AGTTGTCCTTGCATTTTATAAA-
TATGC-30 and I527N2-YR 50-CGAACAATCGCCTCATGAA-30. RT-PCR
assays were done using the KAPA SYBR Fast qPCR Kit (Kapa
Biosystems) on the Rotor Gene Q (Qiagen) and analysed using the
Rotor Gene Q software.
Results
Characteristics of colistin-resistant and susceptible A. baumannii
isolates
Twenty-six non-duplicate colistin-resistant A. baumannii iso-
lates were collected based on Vitek 2 antimicrobial susceptibility
testing. Of these, 20 (62.5%) were confirmed to be colistin-resistant
by both BMD and SensiTest (Figure 1, Supplementary Material
Table S2). These isolates were collected from various microbiolog-
ical specimens including urine, blood culture, tracheal aspirate,
bronchial aspirate, abscess (superficial) aspirate, and tissue, and
samples were obtained from numerous wards. Four colistin-
resistant isolates were isolated in 2016 and 16 in 2017, from tertiary
(n = 15) and district/regional level (n = 4) hospitals and a primary
healthcare clinic (n = 1).
Six colistin-susceptible isolates (AB2, AB3, AB4, AB5, AB9, and
AB11) analysed as part of an outbreak of carbapenem-resistant,
colistin-susceptible A. baumannii in the neonatal unit at a tertiary
hospital, were collected separately between March and May 2017
(Figure 1). These isolates were all collected from blood cultures.
Rep-PCR typing
Thirteen colistin-resistant A. baumannii isolates as well as eight
colistin-susceptible isolates (including five from the neonatal unit
outbreak) were identical by rep-PCR (Figure 2). One neonatal
isolate (AB3) had 88.9% similarity to this strain. The remaining
isolates were all unrelated based on rep-PCR.
The related isolates were all from patients admitted to a
tertiary hospital between May 2016 and August 2017, except for
one isolate (CAC23) from a regional hospital. This isolate wasceptible A. baumannii isolates.
Figure 2. Genetic relatedness of colistin resistant and carbapenem resistant A. baumannii isolates from 2016 and 2017. CAC and AB: A. baumannii, R: Resistant, S: Susceptible,
MIC’s were determined using BMD. HA: Hospital-acquired, CA: Community-acquired. CHC: Community health Centre. CA or HA was only determined for the Tertiary Hospital,
no information about HA or CA at the regional, district and CHC. * WGS was performed.
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tion showed that this patient had been admitted to the same
tertiary hospital 2 weeks previously. All of the related isolates
were not only carbapenem-resistant but also resistant to a further
nine antibiotics (amikacin, cefotaxime, cefepime, ceftazidime,
ciprofloxacin, gentamicin, piperacillin–tazobactam, tobramycin,
trimethoprim–sulfamethoxazole) as determined by Vitek 2
susceptibility testing, giving this strain type an extensively
drug-resistant (XDR) profile.
Genomic investigation into resistance mechanisms, in particular
colistin resistance
WGS was performed on four of the rep-PCR identical isolates:
two colistin-resistant (CAC12 and CAC38) and two colistin-
susceptible (CAC37 and CAC29). All four isolates were identified
as ST1 using the Pasteur scheme. The four isolates were very
closely related with a maximum of 11 SNPs between isolates
(Table 1).
None of the known mcr-1–5 genes were detected in the colistin-
resistant isolates using PCR; this was confirmed in the sequenced
isolates. No mcr-6–9 genes were detected in the WGS data. No
previously described colistin resistance mutations were detected
in the pmr or lpx genes of the colistin-resistant isolates CAC12 and
CAC38, and the sequences of these genes were identical in the two
colistin-resistant and two susceptible isolates. Additional acquired
resistance genes were detected in all four XDR A. baumanniiTable 1
Number of SNP differences between two colistin-susceptible and two colistin-
resistant Acinetobacter baumannii isolates using snp-dists 0.6.3.
Colistin Resistant Susceptible
CAC12 CAC38 CAC37 CAC29
Resistant CAC12 0 2 2 9
CAC38 0 4 11
Susceptible CAC37 0 9
CAC29 0
SNP, single nucleotide polymorphism.isolates (Table 2), which correlated with the susceptibilities of the
Vitek 2 tested antibiotics. Phenotypic testing for macrolides,
rifampicin, sulphonamides, and phenicols is not performed
routinely.
A single non-synonymous mutation was identified in both
colistin-resistant isolates that was absent in both colistin-
susceptible isolates. The I527N mutation was identified in the
2196-bp DctM-like transporter family protein (tripartite ATP-
independent periplasmic transporter); however this protein has
not previously been associated with colistin resistance. Ten of
the 13 clonal colistin-resistant isolates had the I527N mutation.
Three clonal colistin-resistant isolates (CAC14, CAC30, and
CAC47) and all of the other unrelated colistin-resistant isolates
did not have the I527N mutation. The I527N mutation was not
detected in any of the colistin-susceptible isolates. The gene
presence/absence search with Roary did not show any relevant
differences between the colistin-resistant and colistin-suscep-
tible isolates. Roary only showed that CAC38 had a missing
phage compared to the other three isolates. This phage was
determined to be similar to Psychrobacter phage Psymv2
(NC_023734) using the PHAge Search Tool Enhanced Release
(PHASTER) (Arndt et al., 2016).
Discussion
The increase in colistin-resistant A. baumannii isolates from a
tertiary hospital in the Western Cape in 2017 appears to be due to
clonal expansion of an emerging colistin-resistant strain within the
hospital. This strain was not detected in 2016 or in isolates from
other hospitals.
A 2016 surveillance study in South Africa reported that
carbapenem resistance in A. baumannii in South Africa is high
(81%), with consistent findings across sentinel health care facilities,
as well as increasing levels of resistance over time (Perovic et al.,
2018). This limits treatment options, with colistin being the most
commonly used alternative antimicrobial agent. To date no
surveillance data on colistin resistance among A. baumannii
laboratory isolates are available in South Africa.
Table 2
Additional acquired resistance genes in CAC12, CAC38, CAC37, and CAC29.
Resistance Acquired resistance genes











Aminoglycoside aac(3)-Ia, aph(3”)-Ib, aph(3')-Ia,
aadA1, aph(6)-Id, armA
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commonly available antibiotics, and most were resistant to
colistin. The presence of contemporaneous identical colistin-
susceptible strains isolated from the same hospital suggests either
relatively recent acquisition of the colistin resistance mechanism
or perhaps a heteroresistant population in which the respective
mutations have not (yet) become fixed and are thus difficult to
trace genomically. If more than four isolates were sequenced, we
might have found more genetic modifications between the
outbreak isolates.
The absence of plasmid-mediated mcr genes and any known
chromosomal mutations suggests that the colistin resistance in
these isolates may be due to an undescribed mechanism of colistin
resistance. Functionality studies are planned to investigate the
single I527N non-synonymous mutation that was identified in 10
of the 13 clonal colistin-resistant isolates to determine its putative
role in colistin resistance. However, the fact that three of the clonal
colistin-resistant isolates did not have the I527N mutation may
cast doubt on the role of this mutation in colistin resistance.
WGS has been recognized to be more effective than traditional
methods for characterizing outbreaks caused by gram-negative
bacteria; however in this study, rep-PCR showed an accurate
representation of the sequencing results. Various publications
have shown rep-PCR to be more discriminatory than multilocus
sequence typing (MLST) (Runnegar et al., 2010; Hojabri et al.,
2014). The four isolates that underwent WGS showed low SNP
diversity, yet were obtained from different wards in the tertiary
hospital. The sequence type of these clonally related isolates is ST1,
which is part of global clone 1, one of the dominating clones
worldwide (Ewers et al., 2016; Martins et al., 2012; Ghaith et al.,
2017; Handal et al., 2017; Hamidian et al., 2014). Given the
discriminatory power of rep-PCR, it is almost certain that all of the
clonal isolates belong to ST1. ST1 has not been described previously
amongst colistin-resistant A. baumannii.
The phylogenetic relationship of the strains was critical in
guiding infection control measures and restricting the outbreak.
The infection prevention hospital staff were immediately informed
and outbreak intervention measures were intensified, including
active surveillance, hand hygiene, and contact precautions.
Restricting the spread of A. baumannii to reduce rates of
hospital-acquired infections is challenging, because the bacteria
can survive in the environment for long periods. Thorough
environmental cleaning of potential reservoir sources in hospital
environments, e.g. ventilators, humidifiers, suction containers, and
moist articles, is highly recommended.
Limitations
Information regarding whether isolates were hospital- or
community-acquired was only available for patients from thetertiary hospital. However, the clonally related isolates were all
from this hospital, and the isolates from other hospitals were
unrelated. Some colistin-resistant isolates may have been missed,
as only isolates shown to be resistant using Vitek were collected,
and the limitations of the Vitek for colistin susceptibility testing
have been described (Girardello et al., 2018). Likewise, colistin-
susceptible isolates belonging to the same clone may have been
missed, since the primary selection criterion was colistin resis-
tance and the neonatal isolates were included fortuitously. At the
time when isolate collection was initiated, the limitations of
colistin susceptibility testing using automated platforms were not
widely recognized, and it would have been impractical to collect all
A. baumannii isolates, given the large number of isolates coming
through the NHLS laboratory.
Conclusions
A clonal expansion in 2017 of an emerging colistin-resistant A.
baumannii was detected in a tertiary hospital in the Western Cape
of South Africa. The presence of genetically closely related colistin-
susceptible strains in the same hospital during the same time
frame suggests that the acquisition of colistin resistance was
relatively recent. This is the first report of a colistin-resistant clonal
expansion of A. baumannii in South Africa.
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